Navigation Links
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Date:5/7/2012

sure.

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA including endophthalmitis, traumatic cataract, and increased intraocular pressure.

Please see the full Prescribing Information for EYLEA, available online at www.regeneron.com/EYLEA-fpi.pdf.

About Wet AMD
Age-related Macular Degeneration (AMD) is a leading cause of acquired blindness.  Macular degeneration is diagnosed as either dry (non-exudative) or wet (exudative).  In wet AMD, new blood vessels grow beneath the retina and leak blood and fluid. This leakage causes disruption and dysfunction of the retina creating blind spots in central vision, and it can account for blindness in wet AMD patients. Wet AMD is the leading cause of blindness for people over the age of 65 in the U.S. and Europe.

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hyper
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
2. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
3. Regeneron Announces February 2012 Investor Conference Presentations
4. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
5. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
6. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
7. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
8. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
9. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
10. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
11. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2010 Segal McCambridge Singer & Mahoney, Ltd. and ... in favor of medical device manufacturer I-Flow Corporation.  A ... the District of Oregon returned defense verdicts on all ... three plaintiffs whose cases had been consolidated for trial. ...
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of Sangamo,s ZFP Therapeutic® development programs and an ... on Tuesday, November 16, 2010, at the Lazard Capital Markets ... York City. A live webcast of the presentation ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference 2
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... Sky One,Medical, Inc. ("China Sky One Medical" or ... fully integrated pharmaceutical company producing over-the-counter,drugs in the ... it,successfully obtained the production approval from the State ... additional drugs: Sodium Cromoglicate,Eye Drops for the treatment ...
... Re Ltd., the reinsurance unit of White Mountains Insurance Group, Ltd. ... Financial Officer, will retire from full-time work at the end of ... advisor to White Mountains. , , ... the last 7 years Chuck has filled many roles within our ...
... PITTSBURGH, Dec. 16 MED3OOO, Inc., a national healthcare management, ... able to help the City of Newark, Ohio recover lost ... companies. , , After partnering ... of Newark Division Fire & EMS department is now able ...
... Dec. 16 CeloNova BioSciences, Inc., announced,today that ... U.S. Food and,Drug Administration (FDA) for Embozene(TM) Color-Advanced ... tumors (tumors with a,large number of blood vessels ... circulatory system). U.S. commercial sales of,Embozene(TM) Microspheres will ...
... Dec. 16 While all cosmetic surgery,can be performed ... feel or remember their surgery - a condition commonly ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LATU002 ) , ... iv sedation, pioneered by anesthesiologist Dr. Barry L.,Friedberg, is ...
... more efficiently, Fresho.com offers bulk job posting and announces new job ad ... ... NY (PRWEB) December 16, 2008 -- In order to help employers fill ... search engine Fresho.com now offers employers to submit their job openings ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 2Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 4Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 2Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 2Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 4Health News:Cosmetic Surgery -'Goldilocks' Anesthesia Is Not Mickey Mouse 2Health News:Fresho.Com Offers Efficient Job Postings for Employers and Recruiters 2
... Performance ,MARS Technology is the next generation ... an addition to our current family of ... advantage of new technological breakthroughs in signal ... pulse signal resulting in superior performance during ...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... The Nellcor N-20PA Handheld Pulse Oximeter is ... The durable construction of the N-20PA has ... temperatures and conditions it has even ... is conveniently portable for spot check measurements ...
... Nellcor's most popular handheld oximeter has been ... platform and is now compatible with the ... the MAX-FAST Forehead Sensor and SoftCare Nonadhesive ... Oximeter also incorporates Nellcor's latest advanced signal ...
Medicine Products: